In 2019, Lundbeck acquired Alder BioPharmaceuticals (now Lundbeck Seattle BioPharmaceuticals) and with it eptinezumab – a humanised anti-calcitonin gene-related peptide (CGRP) monoclonal antibody.

Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition. If approved by the FDA ...